



> Returnaddress P.O. Box 30945 2500 GX The Hague

Commissariat à l' énergie atomique
Alain Aberman
Responsable projets commerciaux
Centre de Saclay- DEN/DANS/DRSN- Bât.526
91191 Gif-sur-Yvette Cedex
France

**Directoraat-Generaal
Milieu**

Directie Risicobeleid
Straling, Nucleaire en
Bioveiligheid

Rijnstraat 8
P.O. Box 30945
2500 GX The Hague
Internal Postal Code 645
The Netherlands
www.vrom.nl

Contactperson

Dr. M.G. Delfini

T +31 (0)70 339 49 66
F +31 (0)70 339 12 86

Our reference

RB/2009010009

Date February 2, 2009
Subject request of information

Dear mister Alberman,

As you know in these days the Dutch government is discussing the possibility of allowing the operation of the HFR reactor in Petten, in view of the worldwide need of radioisotopes for nuclear medicine. The decision takes into account on the one hand the fact that corrosion has been detected in the primary cooling system of the HFR reactor, and on the other hand the fact that isotopes production is necessary for diagnostic and therapeutic procedures in nuclear medicine.

During the discussion last friday more information was asked about the possibilities to produce isotopes in the other european reactors, the BR2 in Belgium and the OSIRIS in France. This is the reason why I am turning to you as commercial and project manager at the OSIRIS reactor in Saclay.
In order to provide the government with the information they asked for, I would appreciate if you could answer the following questions:

- 1) Where there actions taken at the OSIRIS reactor during the last months (since august 2008) in order to help compensate for the lack of isotopes production following the shut down of the HFR reactor in Petten? What actions were taken?
- 2) Was the scheduling of the isotopes irradiation in the OSIRIS reactor modified with respect to previous planning? Could you give more detail information about that?
- 3) Would it be possible to arrange the scheduling of the isotopes irradiation in the coming months (until the end of 2009) in such a way that lack of production in HFR is compensated for? If not, could you give some information as to the reasons of that? Are there legal, technical of commercial reasons that prevent increased isotope production at OSIRIS?

The discussion in the Dutch government is foreseen for coming friday. In view of that I would appreciate if you could answer within a couple of days (wednesday at the latest). I do apologize for the very short notice and I thank you in advance for your cooperation.

If you have any question of if you need clarification, pleased don't hesitate to contact
mrs. Ginevra Delfini either by phone (+31 70 3394966) or by mail
(ginevra.delfini@minvrom.nl)

I hope to hear from you soon.

Yours sincerely,
director for Environmental Safety & Risk Management,



Peter Tofbijn.

**Directoraat-Generaal
Milieu**
Directie Risicobeleid
Straling, Nucleaire en
Bioveiligheid

Date
February 2, 2009

Our reference
RB/2009010009